Day One Biopharmaceuticals
DAWN
DAWN
87 hedge funds and large institutions have $1.04B invested in Day One Biopharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 29 increasing their positions, 15 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
32% more funds holding
Funds holding: 66 → 87 (+21)
12.68% more ownership
Funds ownership: 69.9% → 82.58% (+13%)
Holders
87
Holding in Top 10
4
Calls
$7.91M
Puts
$2.78M
Top Buyers
| 1 | +$75.8M | |
| 2 | +$46M | |
| 3 | +$33.4M | |
| 4 |
DM
Deerfield Management
New York
|
+$25.5M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$17.6M |
Top Sellers
| 1 | -$8.95M | |
| 2 | -$8.03M | |
| 3 | -$6.44M | |
| 4 |
Millennium Management
New York
|
-$2.81M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$1.37M |